Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report

References

• Fernandez-Cuesta L, Foll M. Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities. Transl Lung Cancer Res. 2019;8(Suppl 4):S430–S434. doi:10.21037/tlcr.2019.11.08
   PubMedGoogle Scholar
• Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015;16(7):e342–e351. doi:10.1016/S1470-2045(15)00077-7
   PubMed Web of Science ®Google Scholar
• Watanabe J, Togo S, Sumiyoshi I, et al. Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review. Oncotarget. 2018;9(35):24000–24013. doi:10.18632/oncotarget.25257
   PubMedGoogle Scholar
• Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490–2498. doi:10.1200/JCO.2016.71.5904
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Bordi P, Bini P, Bidin L, Camisa R, Tiseo M. Enteral administration of TKIs: report of a response to ceritinib in an ALK-positive NSCLC patient and literature review. Curr Drug Targets. 2018;19(14):1649–1656. doi:10.2174/1389450119666180213102939
   PubMed Web of Science ®Google Scholar
• Fan J, Xia Z, Zhang X, et al. The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:1105–1115. doi:10.2147/OTT.S156170
   PubMed Web of Science ®Google Scholar
• Zou Helen Y, Friboulet L, Kodack David P, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–81. doi:10.1016/j.ccell.2015.05.010
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Santarpia M, Gonzalez Cao M, et al. Anaplastic lymphoma kinase inhibitors in Phase I and phase II clinical trials for non-small cell lung cancer. Expert Opin Investig Drugs. 2017;26(6):713–722. doi:10.1080/13543784.2017.1324572
   PubMed Web of Science ®Google Scholar
• Wang H, Sun L, Sang Y, et al. A study of ALK-positive pulmonary squamous-cell carcinoma: from diagnostic methodologies to clinical efficacy. Lung Cancer. 2019;130:135–142. doi:10.1016/j.lungcan.2019.02.015
   PubMed Web of Science ®Google Scholar
• Yang X, Peng P, Zhang L. Multiline treatment of advanced squamous cell carcinoma of the lung: a case report and review of the literature. World J Clin Cases. 2019;7(14):1899–1907. doi:10.12998/wjcc.v7.i14.1899
   PubMed Web of Science ®Google Scholar
• Ding M, Deng L, Yu R, et al. Case report: temporal heterogeneity of ALK activating mutations in sequential ALK TKI-treated non-small-cell lung cancer revealed using NGS-based liquid biopsy. Clin Lung Cancer. 2019;20(3):e229–e232. doi:10.1016/j.cllc.2019.02.014
   PubMed Web of Science ®Google Scholar
• Nagasundaram N, Wilson Alphonse CR, Samuel Gnana PV, Rajaretinam RK. Molecular dynamics validation of crizotinib resistance to ALK mutations (L1196M and G1269A) and identification of specific inhibitors. J Cell Biochem. 2017;118(10):3462–3471. doi:10.1002/jcb.26004
   PubMed Web of Science ®Google Scholar
• Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014;20(22):5686–5696. doi:10.1158/1078-0432.CCR-14-1511
   PubMed Web of Science ®Google Scholar
• Sabari JK, Santini FC, Schram AM, et al. The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers. Onco Targets Ther. 2017;10:1983–1992. doi:10.2147/OTT.S109295
   PubMed Web of Science ®Google Scholar
• Ou SH, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9(4):549–553. doi:10.1097/JTO.0000000000000094
   PubMed Web of Science ®Google Scholar
• Urbanska EM, Sørensen JB, Melchior LC, Costa JC, Santoni-Rugiu E. Changing ALK-TKI-resistance mechanisms in rebiopsies of ALK-rearranged NSCLC: ALK- and BRAF-mutations followed by epithelial-mesenchymal transition. Int J Mol Sci. 2020;21(8):2847. doi:10.3390/ijms21082847
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Rooney M, Lin JJ, et al. Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity. Clin Cancer Res. 2019;25(22):6662–6670. doi:10.1158/1078-0432.CCR-19-1436
   PubMed Web of Science ®Google Scholar
• Qiu D, Zhang Y, Xue YB, et al. Chemotherapy combined with Endostar as salvage treatment for EGFR-tyrosine kinase inhibitor primary resistance in an advanced non-small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: a case report. Thorac Cancer. 2019;10(4):1023–1028. doi:10.1111/1759-7714.13003
   PubMed Web of Science ®Google Scholar
• Wang J, Sun Y, Qin S. Results of Phase IV clinical trial of combining endostar with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC).. J Clin Oncol. 2010;28(15_suppl):7598. doi:10.1200/jco.2010.28.15_suppl.7598
   Google Scholar
• Han B, Xiu Q, Wang H, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(6):1104–1109. doi:10.1097/JTO.0b013e3182166b6b
   PubMed Web of Science ®Google Scholar
• Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011;2011:583929. doi:10.1155/2011/583929
   PubMedGoogle Scholar
• Molina-Vila MA, Bertran-Alamillo J, Gascó A, et al. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2014;20(17):4647–4659. doi:10.1158/1078-0432.CCR-13-2391
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa1810865
   PubMed Web of Science ®Google Scholar